Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — 7th Targeted Radiopharmaceuticals Summit Europe 2025
30 slides from Oncoinvent Asa's conference presentation, Nov 12, 2025
Slide 1: Oncoinvent: Transforming cancer care through direct alpha therapy
Oncoinvent Transforming cancer care through direct alpha therapy TRP Summit Europe – 12 November 2025
Slide 2: Expanding the Scope of Targeted Radiopharmaceuticals
Expanding the Scope of Targeted Radiopharmaceuticals A practical example of direct radiotherapy in peritoneal carcinomatosis Topic o 224Ra labelled microparticles - Radspherin® - to target cancer in body cavities Content o Latest clinical data and development plans for Radspherin® - currently in Pha
Slide 3: Disclaimer (I/II)
Disclaimer (I/II) THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, ITS TERRITORIES OR POSSESSIONS, JAPAN, AUSTRALIA, CANADA, HONG KONG OR SOUTH AFRICA OR TO ANY RESIDENT THEREOF, OR ANY JURISD
Slide 4: Disclaimer (II/II)
Disclaimer (II/II) This Presentation contains information obtained from third parties. Such information has been accurately reproduced and, as far as the Company is aware and able to ascertain from the information published by that third party, no facts have been omitted that would render the reprod
Slide 5: The history of targeted therapeutic radiopharmaceuticals
The history of targeted therapeutic radiopharmaceuticals Use of 131I- Zevalin and First patient labelled Bexxar treated with Approval of Approval of antibodies for 177Lu-DOTATATE approved melanoma for NHL Lutathera Pluvicto 1930 1940 1950 1960 1970 1980 1990 2000 2010 2020 1st therapeutic 1st therap
Slide 6: Ways to target cancer with radiopharmaceuticals
Ways to target cancer with radiopharmaceuticals Natural homing Molecular targeting Direct radiotherapy • Some radionuclides naturally targets • Radioligands: Biological targeting • Physically trapping radioactivity in an certain organs. 223Ra Xofigo goes to agent linked to a radioactive payload orga
Slide 7: Targeting by proximity – brilliant in its simplicity
Targeting by proximity – brilliant in its simplicity Bypasses Retains Increases the need of the radioactive the radionuclide biological targeting payload in the exposure at the and systemic target area tumor target sites distribution of the radioactive payload Reduces the radionuclide exposure to ra
Slide 8: Oncoinvent – directly targeted alpha therapy
Oncoinvent – directly targeted alpha therapy Oncoinvent uses a targeted, non-biological, receptor independent mode of action 1 with the alpha emitter 224Ra 2 Harnessing the advantages of radiopharmaceuticals with lower complexity and risk 2 3 Signals of efficacy: potential game changer in ovarian an
Slide 9: Peritoneal metastases - urgent need for novel treatments
Peritoneal metastases - urgent need for novel treatments • Peritoneal metastases arise from many different primary cancers • The only treatment option with curative intent is surgery, effect of systemic therapy limited • Surgery leaves behind micro-metastases giving rise to new metastases and diseas
Slide 10: The main cause of death in ovarian cancer
The main cause of death in ovarian cancer • The majority of patients experience disease recurrence • Recurrences are almost exclusively confined to the peritoneum • Large clinical need for local control of cancer in the peritoneum is key to improving life expectancy • FDA Fast Track Lengyel Am J Pat
Slide 11: Radspherin® - alpha therapy targeted to and retained in the peritoneum
TREATMENT CONCEPT Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® • Combining alpha-emitting 224Ra with CaCO3 microparticles • Half-life 3.6 days • Therapy with depot effect - 75% of radiation dose delivered the first week • Shelf life 8 days allowing for centraliz
Slide 12: Radspherin® - alpha therapy targeted to and retained in the peritoneum
TREATMENT CONCEPT Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® How does it work? • Combining alpha-emitting 224Ra with • Delivery directly to the peritoneum through CaCO3 microparticles an in-dwelling catheter • Half-life 3.6 days • Administration 1-3 days post-
Slide 13: Properties of the radionuclide radium-224
Properties of the radionuclide radium-224 224Ra 3.63 d α 220Rn • Half life 3.6 days 55.6 s • Decay of radium-224 to stable lead-208 via α shorter-lived daughters 216Po • 4 alpha particles released 0.15 s • 93% of the total decay energy emitted as alpha particles α • The amount of lead resulting from
Slide 14: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 14
Slide 15: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 15
Slide 16: Radspherin® - phase 1 study in ovarian cancer
Radspherin® - phase 1 study in ovarian cancer RAD-18-001: in patients after secondary debulking 4 clinical sites: surgery of platinum-sensitive recurrent ovarian cancer • Oslo, Norway (PI: Yun Wang) • single-arm open label study • Leuven, Belgium (PI: Els van Nieuwenhuysen) • 3 + 3 dose-escalation (
Slide 17: Ovarian cancer: Preventing disease progression
PHASE 1 RESULTS Ovarian cancer: Preventing disease progression 24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates Recurrence rates RAD-18-001 Recurrence rates historical controls “These final results are truly encouraging, suggesting that Radspherin® could help delay
Slide 18: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 18
Slide 19: Design: Phase 1/2a in colorectal cancer
Design: Phase 1/2a in colorectal cancer The trial: (RAD-18-002) Radspherin after Two clinical sites: cytoreductive surgery and HIPEC in patients with peritoneal metastasis from colorectal cancer • Oslo, Norway (PI: Stein Larsen) • Uppsala, Sweden (PI: Wilhelm Graf) • Single-arm open label study • 3
Slide 20: Colorectal cancer: final phase 1/2a data confirm peritoneal control
PHASE 1/2A RESULTS Colorectal cancer: final phase 1/2a data confirm peritoneal control Topline 18-months data of 36 patients receiving 7 MBq dose vs historical recurrence rates Peritoneal recurrence rate "It’s highly encouraging to see Radspherin® Historical control patients treated with Radspherin
Slide 21: Controlling peritoneal disease may significantly improve survival in colorectal cancer
Controlling peritoneal disease may significantly improve survival in colorectal cancer First disease recurrence after treatment 1 Impact of site of first site of recurrence 1 1/3 peritoneal only Median overall survival - from the time of recurrence: 1/3 combined • After distant metastasis only: 44 m
Slide 22: Baseline characteristics
PHASE 1/2A RESULTS Baseline characteristics RAD-18-002 Colorectal cancer (n=36) RAD-18-001 Ovarian cancer (N=21) Age, median (min, max) 64 (28, 78) Age, median (min, max) 65 (55, 79) Gender, n (%) Males 16 (44%) Gender, n (%) Females 21 (100%) Females 20 (56%) PCI, median (min, max) 7.5 (2, 19) PCI,
Slide 23: Safety profile validated in two phase 1/2a studies treating 68 patients
PHASE 1/2A RESULTS Safety profile validated in two phase 1/2a studies treating 68 patients • No dose limiting toxicity Well tolerated and safe to use • Two SAEs possibly related to Radspherin* No evidence of systemic radiation toxicity • Radiation dose retained in the peritoneal cavity • Absorbed do
Slide 24: Near-term significant milestone
Near-term significant milestone Interim data Phase 2 Following complete recruitment ovarian cancer 2H26 Final 24 months data Phase 1 10 patients 7 MBq ovarian cancer October 2025 Final 18 months data Phase 1/2a colorectal cancer 36 patients 7 MBq June 2025 24
Slide 25: Phase 2 study in ovarian cancer – enrollment on track
PHASE 2 PROGRAM Ovarian cancer Phase 2 study in ovarian cancer – enrollment on track All 6 centers active Patients PFS • with peritoneal pPFS metastases SoC+ Radspherin Assessment OS Randomised (60 patients) every 3 months TFST • after neoadjuvant Safety run-in cohort (6 patients) 2:1 up to 24 TSST
Slide 26: Pipeline in one product - broad clinical application
MARKET OPPORTUNITY Pipeline in one product - broad clinical application Extraperitoneal Intraperitoneal origin origin Lung cancer Cholangiocarcinoma Breast cancer Gastric cancer • Peritoneal metastases arise from many Malignant melanoma Pancreatic cancer different cancers Kidney cancer Colorectal Ca
Slide 27: In-house GMP pilot plant
MANUFACTURING AND SUPPLY In-house GMP pilot plant Oncoinvent has in-house GMP 224Ra produced from 228Th, which Microparticles and finished goods production capability has multiple sources produced in-house Capacity of ~200 doses Radspherin annually, outsourcing and scale-up required for phase 3 On s
Slide 28: Radspherin® production process
MANUFACTURING AND SUPPLY Radspherin® production process Overview of the Radspherin® production process Raw material input Combination Final product Elution of the alpha- emitter radium-224 Thorium-228 generator column Radium-224 Labeling of radium-224 to microparticles Pre-made calcium carbonate mic
Slide 29: Ways to target cancer with radiopharmaceuticals
Ways to target cancer with radiopharmaceuticals Natural homing Molecular targeting Direct radiotherapy • Some radionuclides naturally targets • Radioligands: Biological targeting • Physically trapping radioactivity in an certain organs. 223Ra Xofigo goes to agent linked to a radioactive payload orga
Slide 30: Summary
Summary 1 Peritoneal carcinomatosis is an area with high unmet need 1 2 Targeted, non-biological, receptor independent mode of action with alpha emitter 2 3 3 Compatible with established treatment regimes - adds well to existing patient flow 4 4 Signals of efficacy: potential game changer in ovarian
Oncoinvent — 7th Targeted Radiopharmaceuticals Summit Europe 2025 on 6ix